Scholars Central

EditorialPublished 23 Jun 2012

Combinational Treatment for Pancreatic Cancer: Where Are We Standing?

Authors: Andrew M. Albrecht, Jingxuan Yang, Min Li

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pancreatic cancer has one of the highest mortality rates of all cancers, with an incredibly poor prognosis, aggressive metastasis, and limited choice of therapy. Of the estimated 43,920 new cases of pancreatic cancer diagnosed in 2012, only 5.8% are likely to survive beyond 5 years. Currently, surgical resection is the only effective treatment for this devastating disease. However, only around 15% of the patient population is eligible for surgery as most cases are diagnosed at a late stage when surgery is no longer an option. Even for resectable pancreatic cancer, the majority of patients are likely to relapse.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Oncology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Andrew M. Albrecht”
  • BylineArticles whose byline prints “Jingxuan Yang”
  • BylineArticles whose byline prints “Min Li”